Chugai licenses RAF-MEK molecular glue SPYK04 to InxMed in worldwide deal

By Public Technologies
  • Chugai Pharmaceutical licensed SPYK04 to InxMed under an exclusive worldwide deal covering development, manufacturing, commercialization for solid-tumor indications.
  • Chugai to receive an upfront payment, sales-based royalties post-launch, profit share on non-royalty income InxMed collects from sublicensees.
  • SPYK04 is a RAF-MEK “molecular glue” designed to induce an inactive RAF-MEK complex, aiming to block cancer-cell proliferative signaling.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk